Frequently Asked Questions
The factors such as the prevalence of cases of vertigo and the rising demand for oral drugs are acting as the major drivers for the global antivertigo agents market.
Novartis AG (Switzerland), Endo International Inc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Cipla Inc (India), Dr Reddy's Laboratories Ltd (India), Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc (U.S.), Zydus Group (India), Lupin (India), Vintage Labs (India), Abbvie Inc. (U.S.).
The geographical locations analyzed in the report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The market growth is hindered due to the lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global anti-vertigo agents market over a forecast period.
